1 of 1
Story summary
- Merck will pay SciBrunch Therapeutics $400 million upfront for global rights to its experimental cancer drug.
- The agreement represents the latest U.S. licensing of a medicine developed in China.
- Chinese biotech firms usually retain domestic rights while granting overseas licenses for fees, milestones and royalties.
- Merck’s deal follows several other major licensing arrangements between U.S. drugmakers and Chinese biotech companies.